Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab + Methotrexate in Early Rheumatoid Arthritis (ASPIRE)
NCT00236028Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of infliximab in rheumatoid arthritis (RA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Improvement from baseline in clinical signs and symptoms at 54 weeks, Prevention of structural damage at 54 weeks and 1 more. Status: completed.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00236028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236028.